Savara (NASDAQ:SVRA) Stock Price Up 2.5% – Here’s Why

Savara Inc. (NASDAQ:SVRA)’s stock price shot up 2.5% on Friday . The company traded as high as $5.89 and last traded at $5.78. 1,719,076 shares changed hands during mid-day trading, an increase of 0% from the average session volume of 1,714,141 shares. The stock had previously closed at $5.64.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SVRA. Oppenheimer set a $10.00 price objective on shares of Savara in a research report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Guggenheim reissued a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. Finally, UBS Group set a $10.00 price objective on shares of Savara in a research report on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Savara Trading Up 2.5%

The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. The firm’s 50 day simple moving average is $5.53 and its 200-day simple moving average is $5.28. The company has a market capitalization of $1.18 billion, a PE ratio of -10.91 and a beta of 0.32.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities research analysts anticipate that Savara Inc. will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Savara

Several institutional investors have recently bought and sold shares of the business. VR Adviser LLC grew its stake in Savara by 8.4% during the fourth quarter. VR Adviser LLC now owns 13,740,375 shares of the company’s stock worth $82,854,000 after buying an additional 1,059,332 shares during the period. Vanguard Group Inc. grew its stake in Savara by 20.8% during the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock worth $60,551,000 after buying an additional 1,728,453 shares during the period. Nantahala Capital Management LLC boosted its stake in shares of Savara by 5.4% in the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock valued at $31,328,000 after purchasing an additional 450,000 shares during the period. Polar Capital Holdings Plc purchased a new position in shares of Savara in the fourth quarter valued at $50,086,000. Finally, RTW Investments LP purchased a new position in shares of Savara in the fourth quarter valued at $35,893,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.